Belimumab CTD-ILD - Long Term Extension/Follow up to pivotal studies BLISSc-ILD and BEconneCTD-ILD

You may be able to join if

• Participants with SSc-ILD or other CTD-ILDs that have completed either study 218224 or 221672 through to and including the Week 52 visit and are not considered treatment failure, defined as meeting either of the following criteria: INC#1 o Initiation of new immunosuppressive or immunomodulatory medication for SSc or other CTD-related disease activity/progression since joining study 218224 or 221672. o Increase of systemic corticosteroids beyond the allowed limits, for SSc or other CTD-related disease activity/progression since joining study 218224 or 221672 o Discontinuation of study medication during study 218224 or 221672 for any reason.
• Participants with SSc should have an area of uninvolved or mildly thickened skin that, in the opinion of the investigator, would allow subcutaneous (SC) injection at the abdomen or the front, middle region of the thigh.
• Participant is capable and willing to self-administer the study medication or has a caregiver/healthcare professional who is capable and willing to administer the study medication throughout the study
• Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: INC#4 o Is a woman of non-childbearing potential (WONCBP) as defined in Appendix 4 Section 10.4: Contraceptive and Barrier Guidance. OR o Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of <1%, as described in Section 10.4 (Appendix 4: Contraceptive and Barrier Guidance) during the study treatment period and for at least 4 months after the last dose of study intervention. The investigator should evaluate potential for contraceptive method failure (e.g., non-compliance, recently initiated) in relationship to the first dose of study intervention. − A WOCBP must have a negative highly sensitive pregnancy test (urine or serum, as required by local regulations) within 24 hours before the first dose of study intervention. See Section 8.3.5. − If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. − Additional requirements for pregnancy testing during and after study intervention are located in Section 8.3.5. − The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.